Eli Lilly and Company $LLY Shares Acquired by LGT Fund Management Co Ltd.

Key Points

• LGT Fund Management Co Ltd. increased its stake in Eli Lilly and Company by 20.1% during the second quarter, now holding 34,117 shares valued at approximately $26.6 million.
• Insider trades included Director J Erik Fyrwald purchasing 1,565 shares at an average cost of $642.33, increasing his ownership by 2.14%.
• Eli Lilly's latest earnings report showed $6.31 earnings per share, surpassing estimates, with revenues of $15.56 billion, a 37.6% increase year-over-year.

LGT Fund Management Co Ltd. grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 20.1% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 34,117 shares of the company's stock after buying an additional 5,710 shares during the period. Eli Lilly and Company makes up 2.3% of LGT Fund Management Co Ltd.'s investment portfolio, making the stock its 9th biggest holding. LGT Fund Management Co Ltd.'s holdings in Eli Lilly and Company were worth $26,595,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Family CFO Inc acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $54,000. Duquesne Family Office LLC increased its stake in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after acquiring an additional 32,640 shares during the period. Corient IA LLC bought a new stake in Eli Lilly and Company in the first quarter valued at about $570,000. Cutter Capital Management LP bought a new stake in Eli Lilly and Company in the first quarter valued at about $14,866,000. Finally, Emerald Advisors LLC increased its stake in Eli Lilly and Company by 60.8% in the second quarter. Emerald Advisors LLC now owns 1,021 shares of the company's stock valued at $796,000 after acquiring an additional 386 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 over the last three months. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $840.46 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $795.47 billion, a price-to-earnings ratio of 54.93, a P/E/G ratio of 1.14 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The firm's 50-day moving average price is $734.60 and its two-hundred day moving average price is $766.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Berenberg Bank reissued a "hold" rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Finally, DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $933.39.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.